ADAMTS13 and sickle cell disease: There is also an ongoing clinical trial investigating the benefit of recombinant ADAMTS13 therapy in sickle cell disease, which showed no safety signals or dose-limiting toxicities, such as bleeding events, in the Phase I placebo-controlled study [76].